Showing 5541-5550 of 6035 results for "".
- Eyeris Announces Industry-First, Environmentally-Conscious Packaginghttps://modernod.com/news/eyeris-announces-industry-first-environmentally-conscious-packaging/2476959/Nashville-based start-up Eyeris recently announced its daily disposable contact lens that will be launching in January of 2020. Along with the lens, Eyeris created industry-first trial lens packa
- Allegro to Present Clinical Research on the Novel Integrin-Regulating Portfolio at AAOhttps://modernod.com/news/allegro-to-present-clinical-research-on-the-novel-integrin-regulating-portfolio-at-aao/2476956/Allegro Ophthalmics announced that the results of its phase 2 clinical study of risuteganib (Luminate) for the treatment of intermediate nonexudative age-related macular degeneration (AMD) will be presented during AAO
- Novartis Receives FDA Approval for Beovu for Wet AMDhttps://modernod.com/news/novartis-receives-fda-approval-for-beovu-for-wet-amd/2476953/Novartis announced that the FDA approved Beovu (brolucizumab-dbll) injection, also known as RTH258, for the treatment of wet age-related macular degeneration (AMD). Beovu is the first FDA approved anti-VEGF to offer both greater fluid resolution versus aflibercept and the ability to maintain elig
- Johnson & Johnson Vision Launches Worldwide #ConnectedBySight Campaign in Honor of World Sight Dayhttps://modernod.com/news/johnson-johnson-vision-launches-worldwide-connectedbysight-campaign-in-honor-of-world-sight-day/2476949/In honor of World Sight Day on October 10, 2019, Johnson & Johnson Vision has launched a worldwide campaign to share the untold stories of eye care professionals, patients, and organizations who are inspiring the elevation of eye health as a global priority and demonstrating how the world is
- Oculis Announces Dosing of First Patient in Randomized Phase 2b (SKYGGN) Clinical Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-announces-dosing-of-first-patient-in-randomized-phase-2b-skyggn-clinical-trial-of-ocs-01-for-the-treatment-of-inflammation-and-pain-following-cataract-surgery/2476947/Oculis announced the dosing of the first patient in a phase 2b clinical trial evaluating the efficacy and safety of OCS-01 for the treatment of inflammation and pain following cataract surgery. OCS-01 is a unique topical formulation of dexamethasone based on the company’s proprietary
- TECLens and SERVImed Industrial Spa Announce Partnership to Pursue FDA Approval for Transepithelial Corneal Cross-Linkinghttps://modernod.com/news/teclens-and-servimed-industrial-spa-announce-partnership-to-pursue-fda-approval-for-trans-epithelial-corneal-cross-linking/2476941/Medical device manufacturer TECLens announced a partnership with Italian medical device maker SERVimed Industrial Spa aimed at the development and FDA approval of a new combination product to treat keratoconus. The ne
- Optovue to Introduce NetVue Cloud Image Management Solutions at AAOhttps://modernod.com/news/optovue-introduces-netvue-cloud-image-management-solutions-at-aao/2476940/Optovue announced it will introduce NetVue Cloud image management software at the annual AAO meeting in San Francisco. The NetVue software provides quick access to patients’ images and data on a single screen, eliminating the need to open device-specific app
- DORC Obtains 510k Clearance for Launch of EVA Upgrade Enhancementshttps://modernod.com/news/dorc-obtains-510k-clearance-for-launch-of-eva-upgrade-enhancements/2476922/DORC has announced 510(k) clearance for a range of enhancements to the EVA surgical system. The enhancements has been developed in close collaboration with surgeons and deliver both OR efficiency and surgical performa
- Eversight to Offer Preloaded DMEK in DORC Tubehttps://modernod.com/news/eversight-first-to-offer-preloaded-dmek-in-dorc-tube/2476911/Eversight announced it is the first eye bank to prepare preloaded Descemet membrane endothelial keratoplasty (DMEK) tissue in the Melles DORC tube, offering corneal surgeons more preloaded tissue options that further streamline surgeries and reduce cost, according to a company news release. <
- GenSight Biologics Reports Sustained Efficacy and Safety at 96 Weeks in RESCUE Phase 3 Trial of GS010 for the Treatment of LHONhttps://modernod.com/news/gensight-biologics-reports-sustained-efficacy-and-safety-at-96-weeks-in-rescue-phase-3-trial-of-gs010-for-the-treatment-of-lhon/2476910/GenSight Biologics reported the first set of results from week 96 of the RESCUE phase 3 clinical trial, which evaluated the efficacy and safety of a single intravitreal injection of GS010 (rAAV2/2-ND4) in 39 subjects whose visual loss due to 11778-ND4 Leber Hereditary Optic Neuropat